ArticleJMIR AI2025
Machine Learning-Enhanced Quantitative Structure-Activity Relationship Modeling for DNA Polymerase Inhibitor Discovery: Algorithm Development and Validation.
Article in JMIR AI, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Cognitive sovereignty and decolonial public health: reclaiming epistemic authority in the global AI era.Frontiers in public health · 2026Article
- Artificial Intelligence-Enhanced Multi-Algorithm R Shiny Application for Predictive Modeling and Analytics: Case Study of Alzheimer Disease Diagnostics.JMIR aging · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Background: Cisplatin resistance remains a significant obstacle in cancer therapy, frequently driven by translesion DNA synthesis mechanisms that use specialized polymerases such as human DNA polymerase η (hpol η). Although small-molecule inhibitors such as PNR-7-02 have demonstrated potential in disrupting hpol η activity, current compounds often lack sufficient potency and specificity to effectively combat chemoresistance. The vastness of chemical space further limits traditional drug discovery approaches, underscoring the need for advanced computational strategies such as machine learning (ML)-enhanced quantitative structure-activity relationship (QSAR) modeling. Objective: This study aimed to develop and validate ML-augmented QSAR models to accurately predict hpol η inhibition by indole thio-barbituric acid analogs, with the goal of accelerating the discovery of potent and selective inhibitors that could overcome cisplatin resistance. Methods: A curated library of 85 indole thio-barbituric acid analogs with validated hpol η inhibition data was used, excluding outliers to ensure data integrity. Molecular descriptors spanning 1D to 4D were computed in MAESTRO, resulting in 220 features. In total, 17 ML algorithms, including random forest, extreme gradient boosting (XGBoost), and neural networks, were trained using 80% of the data for training and evaluated with 14 performance metrics. Robustness was ensured through hyperparameter optimization and 5-fold cross-validation. Results: Ensemble methods outperformed other algorithms, with random forest achieving near-perfect predictive performance (training mean square error=0.0002; R²=0.9999 and testing mean square error=0.0003; R²=0.9998). Shapley additive explanations analysis revealed that electronic properties, lipophilicity, and topological atomic distances were the most important predictors of hpol η inhibition. Linear models exhibited higher error rates, highlighting the nonlinear relationship between molecular descriptors and inhibitory activity. Conclusions: Integrating ML with QSAR modeling provides a robust framework for optimizing hpol η inhibition, offering both high predictive accuracy and biochemical interpretability. This approach accelerates the identification of potent selective inhibitors and represents a promising strategy for overcoming cisplatin resistance, thereby advancing precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.